Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CarraShield Labs Issued Ground-breaking Patent for Anti-viral Gel Technology Used to Prevent HPV Infections

CarraShield Labs, Inc. announced today that Chief Scientist Dr. Mario Tremblay has been issued a U.S. patent for a radically new gel technology that has been shown to block HPV infections in clinical trials. This is the first non-vaccine treatment ever developed for preventing cancer-causing HPV infections in a form that can be easily applied topically by both men and women of any age.


News provided by

CarraShield Labs, Inc.

Sep 23, 2020, 11:00 ET

Share this article

Share toX

Share this article

Share toX


ST. PETERSBURG, Fla., Sept. 23, 2020 /PRNewswire-PRWeb/ -- CarraShield Labs, Inc. is pleased to announce the issuance of US Patent 10,688,043, the first in a series of patent filings developed by its Chief Scientist, Dr. Mario Tremblay, covering the unique, natural, anti-viral gel technology marketed as CarraShield® and available over-the-counter in a personal lubricant called Divine 9®. The technology uses a highly unique sea algae extract as the active ingredient, resulting in a product that is not only the first of its kind to show efficacy against human papillomavirus (HPV), but also one that is naturally derived. Divine 9 with CarraShield is the first and only personal lubricant formulated with a sea algae extract, commonly referred to as carrageenan, to be FDA-approved as a Class II Medical Device.

Published independent clinical results from the CATCH (Carrageenan-gel Against Transmission of Cervical HPV) McGill University Medical School Phase IIb study shows that women can reduce the risk of contracting cancer and wart-causing HPV infections by using Divine 9 personal lubricant from CarraShield Labs with its patent-protected CarraShield technology. In the CATCH study, the McGill team evaluated the long-term use of Divine 9 by hundreds of women. They found that using Divine 9 personal lubricant in each intimate encounter reduced the number of new HPV infections as compared to using a standard lubricant.

While the HPV vaccine protects against at the most nine strains of the virus, potentially, the carrageenan-based lubricant can provide total protection from HPV.

Post this

CarraShield Labs' patented gel technology was first tested in groundbreaking work at the National Cancer Institute. The National Cancer Institute's in vitro and in vivo studies showed CarraShield Labs' Divine 9 personal lubricant to be highly effective in blocking infection by the human papillomavirus (HPV). This was followed by confirmatory studies at the Albert Einstein College of Medicine and joint work with The Population Council. The in vitro studies also demonstrated the superiority of the patented CarraShield carrageenan versus other carrageenan types, even at low concentrations.

There are approximately 470,000 cases per year of Invasive Cervical Cancer (ICC) globally; comprising 10% of all female cancers and it is the second most prevalent cancer in women after breast cancer. HPV is also strongly linked to penile, vaginal/vulvar and anal cancers as well as being the root cause of genital warts. The detection of oral HPV infection has also increased significantly in the past 10 years, which is linked to a rising number of cases of oral, neck and throat cancers.

The CarraShield gel technology opens up entirely new ways to help prevent HPV-induced cancers and warts above and beyond vaccines. Current HPV vaccines only protect against up to 9 types of HPV virus out of over 200 HPV types. It is estimated that only 107 million women have been vaccinated out of a global population of 2.8 billion. "While the HPV vaccine protects against at the most nine strains of the virus, potentially, the carrageenan-based lubricant can provide total protection from HPV," stated Dr. Eduardo Franco, Principle Investigator, University of McGill Medical School.

The newly patented CarraShield technology works as a protective barrier, with no chemical interactions with the body. The barrier mechanism works to reduce transmission from infected individuals by blocking and containing viral shedding. This barrier technology is now being tested with COVID-19 as a means of reducing the spread and severity of the global pandemic. The Company will also soon begin clinical testing products to prevent oral HPV transmission.

About CarraShield Labs, Inc.
CarraShield Labs, Inc., combines nature with science to create products that improve well-being and overall health. Intensive research has led to the company's proprietary, naturally derived sea algae concentrate called CarraShield®. The first product to contain CarraShield is Divine 9®, a water-based personal lubricant used to help prevent HPV infections in women. For information on distribution and licensing opportunities, contact the company at http://www.carrashieldlabs.com.

SOURCE CarraShield Labs, Inc.

Related Links

http://www.carrashieldlabs.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.